Skip to main content
. 2022 Jun 30;13(4):2118–2131. doi: 10.1002/jcsm.13025

Figure 2.

Figure 2

Prophylactic effect of PF1801 on muscle weakness, muscle weight loss, and muscle inflammation in CIM. (A) The grip strength of CIM mice treated prophylactically (prophylactic Tx) with PF1801 (n = 10), PSL (n = 10), combination of PF1801 and PSL (n = 10), or vehicle (n = 10) and that of non‐CIM mice (n = 4). Two‐way ANOVA test, followed by Dunnett's multiple comparison test. *P < 0.05, **P < 0.01. (B) The mean cross‐sectional area (CSA) of muscle fibres of rectus femoris (quadriceps) and biceps femoris (hamstrings) of the mice on day 14 of CIM (n = 5; vehicle, 5; PSL, 5; PF1801, 5; PSL + PF1801, 4; non‐CIM). Data are presented as mean ± SD. One‐way ANOVA test, followed by Bonferroni post hoc test (all pairs). *P < 0.05, **P < 0.01. (C) The area of necrotic muscle fibres on day 14 of CIM. Data are presented as median ± interquartile range. Kruskal–Wallis test, followed by Dunns test. *P < 0.05, **P < 0.01. (D) The histological scores of the severity of myositis on day 14 of CIM. Data are presented as median ± interquartile range. Kruskal–Wallis test, followed by Dunn's test. *P < 0.05, **P < 0.01. (E) The weight of spleen of the CIM on day 14 of CIM. Data are presented as mean ± SD. One‐way ANOVA test, followed by Bonferroni post hoc test (all pairs). *P < 0.05, **P < 0.01. (F) The body weight of the mice. Data are presented as mean ± SD. Two‐way ANOVA test, followed by Dunnetts multiple comparison test. **P < 0.01. (A–F) Data represent three independent experiments.